2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Molecular Testing, Clinical Procedures, Treatment Considerations, Drug Development, Therapy Sequence, Biological Therapies, Antibody Therapy, Transfusion, Transplantation, Non-Biological Therapies, Chemotherapy, Devices, Pharmacology, Radiation Therapy, Adverse Events, Artificial Intelligence (AI), Deep Learning, Biological Processes, Hematopoiesis, Immune Mechanism, Metabolism, Molecular Biology, Clinical Practice (Health Services and Quality), Clinical Guidelines, Diseases, Genetic Disorders, Hemoglobinopathies, Sickle Cell Disease, Sickle Cell Trait, Immunology, GVHD, Infectious Diseases, Viral, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Metabolic Disorders, Measurable Residual Disease, ALL, Non-Hodgkin Lymphoma, B Cell Lymphoma, Research, AML, Translational Research, MDS, CMML, Clinical Research, Clinical Trials, Epidemiology, Patient-Reported Outcomes, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly, Young Adult
PAPER

4198 Fludarabine/melphalan versus busulfan/fludarabine reduced-intensity conditioning in older patients with AML and MDS undergoing allogeneic hematopoietic stem cell transplantation

Muhammad Kashif Amin, MD, MSc, FACP, Rifqa Amjad2, Nabeeha Noor3, Muhammad Shahzad Sarwar, N/A4, Shah Rukh5, Mehdi Hamadani, MD6, Moazzam Shahzad, MD7, Anson Snow, MD8, Mahmoud Aljurf, MD9, Mary Riwes, DO10, Anurag Singh, MD11, Joseph P McGuirk, DO12, Muhammad Mushtaq, MD13
1 The Mikael Rayaan Foundation Global Research Training Institute (MRF-GRTI), Kansas City, Kansas, United States, U.S. Myeloma Innovations Research Collaborative, Kansas City, Kansas, United States, University of Kansas Medical Center, Kansas City, Kansas, United States
2 The Mikael Rayaan Foundation Global Research Training Institute (MRF-GRTI), Kansas City, Kansas, United States, U.S. Myeloma Innovations Research Collaborative, Kansas City, Kansas, United States, University of Kansas Medical Center, Kansas City, Kansas, United States
3 The Mikael Rayaan Foundation Global Research Training Institute (MRF-GRTI), Kansas City, Kansas, United States, U.S. Myeloma Innovations Research Collaborative, Kansas City, Kansas, United States, University of Kansas Medical Center, Kansas City, Kansas, United States
4 The Pakistan Kidney and Liver Institute and Research Center, Lahore, Punjab, Pakistan
5 The Mikael Rayaan Foundation Global Research Training Institute (MRF-GRTI), Kansas City, Kansas, United States, U.S. Myeloma Innovations Research Collaborative, Kansas City, Kansas, United States, University of Kansas Medical Center, Kansas City, Kansas, United States
6 Medical College of Wisconsin, Milwaukee, Wisconsin, United States
7 H. Lee Moffitt Cancer Center, University of South Florida, Tampa, FL, Tampa, Florida, United States, The Mikael Rayaan Foundation Global Research Training Institute (MRF-GRTI), Kansas City, Kansas, United States
8 UNC Bone Marrow & Stem Cell Transplant Clinic, Chapel Hill, North Carolina, United States
9 King Faisal Specialist Hospital & Research Center, Riyadh, Saudi Arabia, The Mikael Rayaan Foundation Global Research Training Institute (MRF-GRTI), Kansas City, Kansas, United States
10 University of Michigan, Ann Arbor, Michigan, United States
11 The Mikael Rayaan Foundation Global Research Training Institute (MRF-GRTI), Kansas City, Kansas, United States, U.S. Myeloma Innovations Research Collaborative, Kansas City, Kansas, United States, University of Kansas Medical Center, Kansas City, Kansas, United States
12 The Mikael Rayaan Foundation Global Research Training Institute (MRF-GRTI), Kansas City, Kansas, United States, U.S. Myeloma Innovations Research Collaborative, Kansas City, Kansas, United States, University of Kansas Medical Center, Kansas City, Kansas, United States
13 The Mikael Rayaan Foundation Global Research Training Institute (MRF-GRTI), Kansas City, Kansas, United States, U.S. Myeloma Innovations Research Collaborative, Kansas City, Kansas, United States, University of Kansas Medical Center, Kansas City, Kansas, United States

Background:

Reduced-intensity conditioning (RIC) extends transplant eligibility to older and more comorbid patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). Busulfan/fludarabine (BuFlu) and fludarabine/melphalan (FluMel) are the most widely used RIC platforms, yet comparative data in older adults remain limited. We compared overall survival (OS), relapse-free survival (RFS), non-relapse mortality (NRM), and relapse between these regimens.

Methods:

We performed a retrospective analysis of consecutive adults with AML or MDS who underwent first RIC allogeneic hematopoietic cell transplantation (allo-HCT) with FluMel or BuFlu between 2013 and 2021, using publicly available Center for International Blood and Marrow Transplant Research (CIBMTR) P-6144 dataset. Primary endpoints were OS and RFS. Secondary endpoints included NRM and relapse (competing-risk analyses) and cumulative incidence of grade II–IV acute and chronic GVHD. Multivariable Cox models (OS, RFS) and Fine–Gray models (NRM, relapse) adjusted for age, Karnofsky performance status, HCT-CI, disease status, graft source, and transplant era. Inverse-probability-of-treatment weighting and 1:1 propensity-score matching were performed as confirmatory analyses.

Results:

A total of 311 patients were included (median age 63 years; AML 198 [64%], MDS 113 [36%]); 170 received FluMel and 141 received BuFlu. Baseline characteristics were generally balanced. HCT-CI ≥3 was more frequent with FluMel (68% vs 54%, p=0.047), and transplant era distribution differed (p=0.026). Sex, race, KPS, disease type (AML 66% vs 60%), disease status, graft source (peripheral blood 93% vs 91%), and donor age were similar (all p>0.10).On univariable analysis, BuFlu was associated with superior OS (HR 0.69, 95% CI 0.50–0.95, p=0.025) and RFS (HR 0.70, 95% CI 0.51–0.95, p=0.022). This was driven by lower NRM (sHR 0.54, 95% CI 0.35–0.83, p=0.005), while relapse risk was similar (sHR 1.10, 95% CI 0.70–1.72, p=0.68). On multivariable analysis adjusting for age, KPS, HCT-CI, disease status, graft source, and transplant era, BuFlu remained independently associated with superior OS (HR 0.68, 95% CI 0.48–0.96, p=0.026) and RFS (HR 0.69, 95% CI 0.49–0.96, p=0.026). The survival benefit was driven by significantly lower NRM (sHR 0.54, 95% CI 0.34–0.85, p=0.007); relapse risk did not differ (sHR 1.09, 95% CI 0.67–1.77, p=0.72). Results were consistent with inverse-probability-of-treatment weighting (OS HR 0.71, p=0.050) and 1:1 propensity-score matching (OS HR 0.66, p=0.022). The survival advantage was preserved in clinically relevant subgroups, including AML-only (HR 0.58, 95% CI 0.36–0.94, p=0.027), age ≥60 years (HR 0.61, 95% CI 0.40–0.93, p=0.021), and KPS <90% (HR 0.62, 95% CI 0.38–0.995, p=0.047).

Conclusions:

BuFlu RIC was associated with lower non-relapse mortality and improved overall and relapse-free survival compared with FluMel in older patients with AML and MDS, without an increase in relapse. These results were robust across multivariable, propensity-score, and subgroup analyses. Prospective confirmation is warranted.

Muhammad Kashif Amin, MD, MSc, FACP: No relevant conflicts of interest to declare.